Toggle navigation
Home
Search
Services
Blog
Contact
About
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara
Biocryst Pharmaceuticals, Inc., Birmingham, AL, United States
Search 146 grants from Y Babu
Search grants from Biocryst Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Live, oral, heat Stable S. typhi TY21a vaccine
Women's Health Agenda
Geometric Flows and Analysis on Metric Spaces
Asymmetric Circulation in Wind-Driven Bays
SBIR Phase I: Aerosolized Biological Agents Detection
Recently added grants:
Myocardial Radiomics and Mechanics in the Pathology and Prognosis of Cardiovascular Disease
Bio-tribo-corrosion resistant 3D Printed Composites for Load-bearing Implants
Brain-selective estrogen therapy for menopausal hot flushes in an advanced translational animal model
Expanding the known coding genome: identifying biological function for novel tORFs
Technology Facilitated Behavioral Intervention for Depression among Diverse Patients in Ambulatory Oncology
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AR041095-03
Application #
2080467
Study Section
Special Emphasis Panel (ZRG7-SSS-6 (06))
Project Start
1994-02-16
Project End
1996-02-15
Budget Start
1995-04-05
Budget End
1996-02-15
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Biocryst Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
Related projects
NIH 1995
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
NIH 1994
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant